Compare RXST & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXST | XOMA |
|---|---|---|
| Founded | 1997 | 1981 |
| Country | United States | United States |
| Employees | 498 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.6M | 308.6M |
| IPO Year | 2021 | N/A |
| Metric | RXST | XOMA |
|---|---|---|
| Price | $7.46 | $25.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $11.50 | ★ $60.60 |
| AVG Volume (30 Days) | ★ 967.1K | 180.6K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,479,000.00 | N/A |
| Revenue This Year | $2.68 | $77.29 |
| Revenue Next Year | $10.07 | $29.30 |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.62 | $18.40 |
| 52 Week High | $29.00 | $39.92 |
| Indicator | RXST | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 33.41 | 53.13 |
| Support Level | $7.40 | $23.71 |
| Resistance Level | $9.13 | $27.73 |
| Average True Range (ATR) | 0.53 | 1.23 |
| MACD | 0.03 | 0.38 |
| Stochastic Oscillator | 14.21 | 78.20 |
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.